Psychiatric symptom – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 18 Jun 2026 04:07:07 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Psychiatric symptom – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Melatonin and Low-Dose Quetiapine for Patients with Psychiatric Disorders and Insomnia https://clinicaltrials.eu/trial/study-on-melatonin-and-low-dose-quetiapine-for-patients-with-psychiatric-disorders-and-insomnia/ Wed, 29 Apr 2026 14:23:46 +0000 https://clinicaltrials.eu/trial/study-on-melatonin-and-low-dose-quetiapine-for-patients-with-psychiatric-disorders-and-insomnia/ This clinical trial is focused on studying the effectiveness of treatments for patients who have psychiatric disorders along with insomnia, which is a condition where people have trouble sleeping. The trial will test the use of melatonin, a hormone that helps regulate sleep, and quetiapine, a medication often used to treat mental health conditions, against a placebo. The purpose of the study is to see how well these treatments work when added to the usual care that patients are already receiving.

Participants in the study will be randomly assigned to receive either melatonin, low-dose quetiapine, or a placebo. The study will last for a period of six months, during which participants will take the assigned treatment orally in the form of film-coated tablets. Throughout the study, participants will be monitored to assess the severity of their insomnia and their overall well-being.

The trial aims to provide insights into how these treatments can help improve sleep quality and daily functioning in individuals with psychiatric disorders and insomnia. By comparing the effects of melatonin and quetiapine to a placebo, researchers hope to determine the most effective approach to managing these conditions together.

]]>